Quick Answer
Olema Pharmaceuticals, Inc. reported R&D Expense of $157.70 million for fiscal year 2025.
Olema Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $157.70M | +26.6% |
| 2024 | $124.52M | +44.6% |
| 2023 | $86.14M | +4.7% |
| 2022 | $82.27M | +61.0% |
| 2021 | $51.10M | +272.9% |
| 2020 | $13.70M | +249.6% |
| 2019 | $3.92M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $39.95M | +20.2% | -9.0% |
| June 30, 2025 | $43.90M | +50.8% | +43.4% |
| March 31, 2025 | $30.62M | +2.5% | -7.8% |
| September 30, 2024 | $33.23M | +70.8% | +14.1% |
| June 30, 2024 | $29.11M | +61.8% | -2.6% |
| March 31, 2024 | $29.88M | +30.9% | +53.6% |
| September 30, 2023 | $19.45M | +10.4% | +8.1% |
| June 30, 2023 | $17.99M | -33.5% | -21.2% |
- Olema Pharmaceuticals, Inc. showed an increase of +26.6% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Olema Pharmaceuticals, Inc.’s r&d expense has grown by 3922.9% (from $3.92 million to $157.70 million).
- The most recent figure is from Olema Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: